Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
出版年份 2014 全文链接
标题
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
作者
关键词
-
出版物
JOURNAL OF LIPID RESEARCH
Volume 55, Issue 10, Pages 2103-2112
出版商
American Society for Biochemistry & Molecular Biology (ASBMB)
发表日期
2014-08-20
DOI
10.1194/jlr.m051326
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Transintestinal Cholesterol Excretion Is an Active Metabolic Process Modulated by PCSK9 and Statin Involving ABCB1
- (2013) Cédric Le May et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics
- (2013) Evan A. Stein et al. Current Atherosclerosis Reports
- An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia
- (2013) Scott M. Grundy Journal of Clinical Lipidology
- Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression
- (2013) Rex A. Parker et al. JOURNAL OF LIPID RESEARCH
- Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy
- (2013) Peter Libby NEW ENGLAND JOURNAL OF MEDICINE
- Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol
- (2013) Susan Kühnast et al. PLoS One
- Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
- (2012) Maxime Denis et al. CIRCULATION
- The PCSK9 decade
- (2012) Gilles Lambert et al. JOURNAL OF LIPID RESEARCH
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
- (2012) James M. McKenney et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
- (2012) Evan A Stein et al. LANCET
- The biology and therapeutic targeting of the proprotein convertases
- (2012) Nabil G. Seidah et al. NATURE REVIEWS DRUG DISCOVERY
- Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
- (2012) Evan A. Stein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
- (2012) Eli M. Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: Result from a crossover study
- (2011) Masa-aki Kawashiri et al. CLINICA CHIMICA ACTA
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
- (2011) et al. EUROPEAN HEART JOURNAL
- Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin
- (2011) Susan Kühnast et al. JOURNAL OF HYPERTENSION
- Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation
- (2010) George S. Abela Journal of Clinical Lipidology
- PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
- (2010) Marianne Benn et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia
- (2009) Bertrand Cariou et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice
- (2008) José W.A. van der Hoorn et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin
- (2008) Willeke de Haan et al. CIRCULATION
- LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms
- (2008) Lars Verschuren et al. JOURNAL OF LIPID RESEARCH
- Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
- (2008) Janice Mayne et al. Lipids in Health and Disease
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
- (2008) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice
- (2007) Willeke de Haan et al. ATHEROSCLEROSIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now